

GLAXOSMITHKLINE PLC  
Form 6-K  
February 24, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending February 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors and  
Persons Discharging Managerial Responsibility**

**Vesting of awards made under GlaxoSmithKline's share plans in 2006**

This notification, prepared in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a), sets out the vesting of share options made in 2006, under the GlaxoSmithKline Share Option Plan.

The three-year performance period for the GlaxoSmithKline Share Option Plan awards made to appointed CET members in 2006, at an option price of £14.68 (or US\$51.02 in the case of ADSs), which commenced on 1 January 2006, came to an end on 31 December 2008. The performance conditions for this grant were not fully met for awards made to the then Executive Directors and CET members who are all persons discharging managerial responsibility. The Remuneration Committee of the Board of GlaxoSmithKline therefore confirmed that 50.7% of the original grant was exercisable.

**Number of options  
over Shares/ADSs  
exercisable**

	<b>Shares</b>	<b>ADSs</b>
Mr A P Witty*	89,993	
Mr J S Heslop*	117,117	
Mr J M Clarke	89,993	
Mr M Dunoyer	35,490	
Mr D J Phelan		44,997
Mr D Pulman		29,153

\* denotes an Executive Director

Grants made in 2006, to senior executives who have since been appointed Executive Directors or CET members were not subject to performance conditions. The Remuneration Committee therefore confirmed that the whole of the original grant was exercisable.

**Number of options  
over Shares/ADSs**

**exercisable**

	<b>Shares</b>	<b>ADSs</b>
Dr M Slaoui*	68,520	
Mr S M Bicknell	12,650	
Mr E J Gray	26,800	
Mr D Learmouth	12,650	
Mr D S Redfern	26,800	
Ms C Thomas	20,180	
Mr J R Stephenne	68,520	
Mr W C Louv		11,870

\*denotes an Executive Director

The Company, Directors, and Persons Discharging Managerial Responsibility were advised of these transactions on 23 February 2009.

**V A Whyte**  
**Deputy Company Secretary**

24 February 2009

**Enquiries:**

UK Media enquiries: Philip Thomson (020) 8047 5502  
 David Outhwaite (020) 8047 5502  
 Stephen Rea (020) 8047 5502

US Media enquiries: Nancy Pekarek (919) 483 2839  
 Mary Anne Rhyne (919) 483 2839  
 Kevin Colgan (919) 483 2839  
 Sarah Alspach (215) 751 7709

European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564  
 Sally Ferguson (020) 8047 5543  
 Gary Davies (020) 8047 5503

US Analyst/ Investor enquiries: Tom Curry (215) 751 5419  
 Jen Hill (215) 751 7002

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: February 24 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc